RxDoctor Payments Data

Diana Alvarez, MD

Cardiovascular Disease · Chattanooga, TNNPI 1285096099

Payments from drug & device makers

$2,723in general payments, 2019–2025

Across 80 payments — averaging $34.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$446
  • E.r. Squibb & Sons, L.L.C.$395
  • Boston Scientific$321
  • Novartis$276
  • Atricure, Inc.$214
  • AbbVie$162
  • plus $911 from 16 others

What the payments were for

  • Food & beverage$2,62496%
  • Education$994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,723 in reported general payments places this provider in the 50th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$87,783
Medicare patients
548
Services billed
1,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan155$180,253
FarxigaDapagliflozin Propanediol123$142,412
EliquisApixaban110$114,554
JardianceEmpagliflozin47$73,378
XareltoRivaroxaban53$63,124
Repatha SureclickEvolocumab11$12,860
VascepaIcosapent Ethyl11$5,692
Ranolazine ErRanolazine40$5,470
Ezetimibe104$3,723
Atorvastatin Calcium282$3,330
Rosuvastatin Calcium229$2,975
Metoprolol Succinate230$2,222
Losartan Potassium225$2,207
Carvedilol265$2,099
Nifedipine ErNifedipine65$1,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$276$180,253155 claims
AstraZenecaFarxiga$19$142,412123 claims
PfizerEliquis$102$114,554110 claims
Boehringer IngelheimJardiance$40$73,37847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →